Medtronic, a medical technology company, and AI-powered personalized nutrition platform Nutrino, have entered into a partnership. The FoodPrint Report technology of Nutrino is slated to be integrated into the iPro2myLog app of Medtronic, a platform which offers continuous glucose monitor enabling users to gain critical insights into their glucose levels.
U.S. Food and Drug Administration officially approved the weekly injection of semaglutide under the brand name of Ozempic. This therapy along with healthy diet and exercise would improve glycemic control in adults with type 2 diabetes. The side effects of semaglutide was found to be mild or moderate nausea.
The newly launched site will also provide details on the effect that food intake, exercise, and medication can have on control glucose levels along with color-coded graph and charts which are focused at usability, bolus tracking features, amplified insulin pump reports, and statistics.
It was great news in the field of medicine when geneticists from University of California, Los Angeles (UCLA) created a novel technique to hunt for natural hormones that would enhance cell communication to play a major role in treating obesity, diabetes and cardiovascular diseases. Scientists discovered two hormones called "notum" and "lipocalin-5", which would aid in the fat burning process. Lipocalin-5 also enhances metabolism and absorption of dietary nutrients by reducing the risk of diabetes and obesity.
Diabetes Australia's (the third oldest diabetes association in the world) latest figures show that over 200,000 women have suffered gestational diabetes during the last 10 years and is expected to exceed 500,000 within the next decade. Gestational diabetes can be fatal if untreated and could likely lead to overweight babies, premature births, as well as PreEclampsia.
Use of an artificial pancreas is associated with better control of blood sugar levels for people with type 1 diabetes compared with standard treatment, finds a review of the available evidence published by The BMJ today.
Eli Lilly and Company and Sigilon Therapeutics, a privately held biopharmaceutical company, announced a global collaboration to develop encapsulated cell therapies for potentially treating Type 1 diabetes. The deal is worth up to $473 million. Sigilon is focused on discovering and developing “living therapeutics” using its Afibromer technology product platform.
The European Medicines Agency (EMA) has accepted for review Sanofi’s regulatory submission for sotagliflozin. If approved, the oral treatment would be used as an addition to insulin therapy to improve blood sugar control in adults with type 1 diabetes mellitus.
This week, Bigfoot Biomedical announced a $55 million Series B to advance their push to integrate glucose monitoring, insulin delivery and smart software. The financing will support a pivotal trial and other efforts to gain premarket approval(PMA) from the FDA.
your submission has already been received.
Please enter a valid Email address！
The most relevant industry news & insight will be sent to you every two weeks.